Noël G, Feuvret L, Ferrand R, Mazeron J-J
Centre de protonthérapie d'Orsay (CPO), BP 65, 91402 cedex, Orsay, France
Cancer Radiother. 2003 Oct;7(5):340-52. doi: 10.1016/s1278-3218(03)00113-6.
Neutrons have radiobiological characteristics, which differ from those of conventional radiotherapy beams (photons) and which offer a theoretical advantage over photons to fight radioresistance by the differential relative biological effect of them between normal and tumour tissues. Neutron therapy beneficed of great interest between 1975 and 1985. Many of phase III trials were conducted and indications have been definitively deducted of them. After briefly describing the properties of neutron beams, this review discusses the indication of neutron therapy on the basis of the clinical results. Salivary, prostate tumours and sarcomas are the main indications of neutron therapy. In concern to the prostate cancers, other alternative treatments reduce the neutron therapy field. For sarcomas, the lack of randomised trials limits the impact of the interest of neutrons. For other tumours, the ratio benefice/risk of neutron therapy is inferior to these obtained with photons and they could not be considered like classical indications.
中子具有放射生物学特性,与传统放疗束(光子)不同,并且通过其在正常组织和肿瘤组织之间的差异相对生物学效应,在对抗放射抗性方面相对于光子具有理论优势。1975年至1985年间,中子治疗备受关注。进行了许多III期试验,并从中明确得出了适应症。在简要描述中子束的特性后,本综述根据临床结果讨论了中子治疗的适应症。唾液腺肿瘤、前列腺肿瘤和肉瘤是中子治疗的主要适应症。对于前列腺癌,其他替代治疗缩小了中子治疗的领域。对于肉瘤,缺乏随机试验限制了中子治疗优势的影响。对于其他肿瘤,中子治疗的获益/风险比低于光子治疗,因此它们不能被视为经典适应症。